^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) + defactinib (VS-6063) (FAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 2 Study of VS-6766 Alone and In Combination with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201) Estudio de fase 2 de VS-6766, solo y en combinación con defactinib en el cáncer de ovario seroso, de bajo grado y recidivante
Excerpt:
...Tumor with known KRAS mutational status using a validated testingmethod (blood or tissue) prior to treatment assignment. ...
Trial ID:
Source:
Title:
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Excerpt:
...- In Part A KRAS mutation, KRAS wt...
More C2 evidence
Source:
Title:
Phase I Trial of Defactinib and VS-6766.
Excerpt:
...Histologically or cytologically proven advanced non-small-cell lung cancer (NSCLC) with a documented KRAS mutation, refractory to conventional treatment, or for which...
Trial ID:
Less C2 evidence
Source:
Title:
Drug combination shows promise in treatment-resistant advanced ovarian cancer
Published date:
09/19/2021
Excerpt:
...tested the drugs – called VS-6766 and defactinib – in 25 patients with low-grade serous ovarian cancer....Overall, nearly half (46 per cent) of patients saw their tumours shrink significantly in response to the treatment....Responses in patients who had a mutation in a gene called KRAS were even more promising....Nearly two-thirds of patients with a KRAS mutation (64 per cent) saw their tumour shrink following treatment...
Trial ID:
Source:
Title:
725MO - Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
Published date:
09/19/2021
Excerpt:
Of the 24 evaluable patients, 11 (46%) had KRAS mutations...The overall response rate in all patients was 46% (11/24, 95% CI: 28% to 65%), with ORR of 64% (7/11, 95% CI: 35% to 85%) in patients with KRAS mutations...n intermittent dosing schedule of the combination of VS-6766 and defactinib has shown encouraging clinical activity in patients with recurrent LGSOC.
DOI:
10.1016/annonc/annonc703
Trial ID:
Source:
Title:
Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting
Published date:
04/27/2020
Excerpt:
...investigator-initiated Phase 1 clinical study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors....The preliminary data reported in the study suggest that a novel intermittent dosing schedule of RAF/MEK and FAK inhibitor combination therapy has promising clinical activity in patients with KRAS mutant LGSOC and KRASG12V mutant NSCLC, including patients previously treated with a MEK inhibitor.
